Search

Displaying results 3981 - 3990 of 10000 in total
  1. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

    Categories: Heterocyclic Compounds, 1-Ring
  2. Drug

    Fasedienol

    go.drugbank.com/drugs/DB04968
    Investigational

    It is a member of a new family of pharmaceutical compounds called vomeropherins. … PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder).

  3. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    It is being developed by Peptech. … PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.

  4. Drug

    Pidotimod

    go.drugbank.com/drugs/DB11364
    Investigational

    Pidotimod is a synthetic dipeptide with immunomodulatory properties.[A7956]

    Categories: Heterocyclic Compounds, 1-RingProducts: ADIMOD®, BRONCOTIMOD ® SOLUCION
  5. Drug

    LS11

    go.drugbank.com/drugs/DB05918
    Investigational

    LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. … It is used to treat many kinds of cancers.

  6. Drug

    ETC-588

    go.drugbank.com/drugs/DB05456
    Experimental

    Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes. … It is believed that the removal of cholesterol by ETC-588 through this pathway may result in the reversal of atherosclerosis.

  7. Drug

    INCB7839

    go.drugbank.com/drugs/DB05033
    Investigational

    INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. … It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.

  8. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    MAXY-G34 is a pegylated variant of human granulocyte-colony stimulating factor (G-CSF). … MAXY-G34 is pegylated with 5 kd mPEG SPA (succinimidyl propionate) groups at 3 amino acid residues, including PEG groups attached at the amino terminal end of the protein and at two internal lysine residues

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    BHV-1300

    go.drugbank.com/drugs/DB22673
    Investigational

    BHV-1300 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.

  10. Drug

    Suramin

    go.drugbank.com/drugs/DB04786
    Investigational

    Suramin is manufactured by Bayer in Germany as Germanin®. … A polyanionic compound with an unknown mechanism of action.